9月10日，诺诚健华盘中下跌5.73%，报13.65港元/股，成交额7165.41万港元。
诺诚健华所在的生物科技行业整体表现疲弱，个股中，信达生物跌3.11%，康方生物跌1.1%，三生制药跌3.59%，百济神州跌0.77%，云顶新耀跌7.43%。
诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司，专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，主要产品管线包括奥布替尼、坦昔妥单抗、ICP-488、ICP-332等，在国内和国外市场开展业务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.